MannKind Corp. (MNKD)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$3.19-0.31%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge MannKind Corp.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-86.1% · beyond scale

+10% or more+5%0%−5%−10% or less

0.02 → 0.00 EPS · FY ending Dec 31, 2027 · 5 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 5 to 5; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	132.86M
EPS	—	-0.01
Annual ending 2026-12-31
Revenue	—	440.12M
EPS	—	-0.19
Annual ending 2027-12-31
Revenue	—	504.97M
EPS	—	0.003

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Improve earnings per share to positive territory	A primary condition in MannKind Corp.'s published investment case. The stated target is EPS >= $0.09.	Broken	EPS remains negative or below $0.05 in FY26	Diluted EPS: $-0.06 per share FY2026-Q2; GAAP. Published target: EPS >= $0.09. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026-0.06 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: cee0ba5e-c0cf-43a6-965a-8118deec64dd. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve revenue of $349 million in 2026	A primary condition in MannKind Corp.'s published investment case. The stated target is >= $349 million.	Intact	annual revenue falls below $300 million in FY26	Revenue: $109.374M FY2026-Q2; GAAP. Published target: >= $349 million. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026109,374,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: cee0ba5e-c0cf-43a6-965a-8118deec64dd. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Successful integration of strategic partnership and acquisition	The company has formed a strategic partnership and completed an acquisition to strengthen its pipeline.	Improving	Partnerships or acquisitions fail to contribute or cause operational disruption	Qualitative: Q2 rev beat + Afrezza approval Q2 2026 revenue beat guidance; Afrezza FDA approval received; new launches lifted outlook at H.C. Wainwright conference. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$0.00

$0.14 → $0.00 · observed estimates

FY2027 revenue$0.50B

$0.52B → $0.50B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$0.14	$521,572,599	5 / 6
2026-07-25	Unavailable	$521,576,120	4 / 8
2026-07-26	Unavailable	$521,576,120	4 / 8
2026-07-27	$0.14	$521,572,599	5 / 6
2026-07-28	Unavailable	$522,338,620	4 / 8
2026-07-29	Unavailable	$522,338,620	4 / 8
2026-07-30	$0.18	$522,372,600	5 / 6
2026-07-31	Unavailable	$522,338,620	4 / 8
2026-08-01	$0.18	$522,372,600	5 / 6
2026-08-02	Unavailable	$522,338,620	4 / 8
2026-08-03	Unavailable	$522,338,620	4 / 8
2026-08-04	$0.16	$526,847,600	5 / 6
2026-08-05	$0.16	$526,847,600	5 / 6
2026-08-06	$0.16	$526,847,600	5 / 6
2026-08-07	$0.02	$509,888,625	5 / 6
2026-08-08	Unavailable	$514,692,120	2 / 8
2026-08-09	Unavailable	$514,692,120	2 / 8
2026-08-10	$0.02	$509,888,625	5 / 6
2026-08-12	Unavailable	$503,979,620	4 / 8
2026-08-13	Unavailable	$503,979,620	4 / 8
2026-08-14	$0.02	$509,888,625	5 / 6
2026-08-15	$0.02	$509,888,625	5 / 6
2026-08-16	$0.02	$509,888,625	5 / 6
2026-08-17	$0.02	$509,888,625	5 / 6
2026-08-18	$0.02	$509,888,625	5 / 6
2026-08-19	$0.02	$509,888,625	5 / 6
2026-08-20	$0.02	$504,017,125	5 / 6
2026-08-21	$0.02	$504,017,125	5 / 6
2026-08-22	$0.02	$504,017,125	5 / 6
2026-08-23	$0.02	$504,017,125	5 / 6
2026-08-24	$0.02	$504,017,125	5 / 6
2026-08-25	$0.02	$504,017,125	5 / 6
2026-08-26	$0.02	$504,017,125	5 / 6
2026-08-27	$0.02	$504,017,125	5 / 6
2026-08-28	$0.02	$504,017,125	5 / 6
2026-08-29	$0.02	$504,017,125	5 / 6
2026-08-30	$0.02	$504,017,125	5 / 6
2026-08-31	$0.02	$504,017,125	5 / 6
2026-09-01	$0.02	$504,017,125	5 / 6
2026-09-02	$0.02	$504,017,125	5 / 6
2026-09-03	$0.02	$504,017,125	5 / 6
2026-09-04	$0.02	$504,019,912	5 / 6
2026-09-05	$0.02	$504,019,912	5 / 6
2026-09-06	$0.02	$504,019,912	5 / 6
2026-09-07	$0.02	$504,019,912	5 / 6
2026-09-08	$0.02	$504,019,912	5 / 6
2026-09-09	$0.02	$504,019,912	5 / 6
2026-09-10	$0.02	$504,019,912	5 / 6
2026-09-11	$0.02	$504,019,912	5 / 6
2026-09-12	$0.02	$504,019,912	5 / 6
2026-09-13	$0.02	$504,019,912	5 / 6
2026-09-14	$0.02	$504,019,912	5 / 6
2026-09-15	$0.02	$504,019,912	5 / 6
2026-09-16	$0.02	$504,019,912	5 / 6
2026-09-17	$0.02	$504,019,912	5 / 6
2026-09-18	$0.02	$504,019,912	5 / 6
2026-09-19	$0.02	$504,019,912	5 / 6
2026-09-20	$0.02	$504,019,912	5 / 6
2026-09-21	$0.02	$504,019,912	5 / 6
2026-09-22	$0.02	$504,019,912	5 / 6
2026-09-23	$0.02	$504,019,912	5 / 6
2026-09-24	$0.02	$504,019,912	5 / 6
2026-09-25	$0.02	$504,019,912	5 / 6
2026-09-26	$0.02	$504,019,912	5 / 6
2026-09-27	$0.02	$504,019,912	5 / 6
2026-09-28	$0.02	$504,019,912	5 / 6
2026-09-29	$0.02	$504,019,912	5 / 6
2026-09-30	$0.02	$504,019,912	5 / 6
2026-10-01	$0.02	$504,019,912	5 / 6
2026-10-02	$0.02	$504,019,912	5 / 6
2026-10-03	$0.02	$504,019,912	5 / 6
2026-10-04	$0.02	$504,019,912	5 / 6
2026-10-05	$0.02	$504,019,912	5 / 6
2026-10-06	$0.02	$504,019,912	5 / 6
2026-10-07	$0.02	$504,019,912	5 / 6
2026-10-08	$0.00	$503,103,912	5 / 6
2026-10-09	$0.00	$503,103,912	5 / 6
2026-10-10	$0.00	$503,103,912	5 / 6
2026-10-11	$0.00	$503,103,912	5 / 6
2026-10-12	$0.00	$503,103,912	5 / 6
2026-10-13	$0.00	$503,103,912	5 / 6
2026-10-14	$0.00	$503,038,687	5 / 6
2026-10-15	$0.00	$503,038,687	5 / 6
2026-10-16	$0.00	$503,038,687	5 / 6
2026-10-17	$0.00	$503,038,687	5 / 6
2026-10-18	$0.00	$503,038,687	5 / 6
2026-10-19	$0.00	$503,038,687	5 / 6
2026-10-20	$0.00	$504,909,689	5 / 6
2026-10-21	$0.00	$504,965,244	5 / 6
2026-10-22	$0.00	$504,965,244	5 / 7
2026-10-23	$0.00	$504,965,244	5 / 7
2026-10-24	$0.00	$504,965,244	5 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	7	1
2026-06-01	7	1
2026-07-01	7	1
2026-08-01	7	1
2026-09-01	7	1
2026-10-01	8	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 8 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades2 maintains

Recent actions · Sep 25–Oct 24 · 2 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Chardan CapitalOct 19

$10.00New observation · no comparable prior

$0$5.50$11.00

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Improve earnings per share to positive territoryPublished status: Broken
Achieve revenue of $349 million in 2026Revenue: $109.374M

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.3%Typical daily move · historical

Downside history

-63.3%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

MannKind Corp. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a loss-making growth business with commercial expansion and clinical development, not a proven durable compounder. The long-term thesis is intact, but elevated risk and medium overall confidence keep it dependent on execution.

What's priced into MannKind Corp.

The evidence describes MNKD as cheap versus peers, while the expectations gap is negative and model confidence is low. The priced-in tag is justified, with no fragility gates triggered, but the valuation evidence is too uncertain to draw a firm conclusion about how much optimism is already reflected.

What the fundamentals likely do

Near term, revenue has grown, helped by Furoscix and the Afrezza pediatric launch, and management is making progress on clinical programs. Reaching the 2026 revenue guidance remains uncertain, and a recent earnings miss plus a run of consecutive misses raise execution risk into the next report. Over the multi-year view, progress depends on continued commercial expansion and development milestones.

What MannKind Corp. hinges on

Meeting revenue guidance and continuing to diversify the commercial portfolio are key swing factors. A guidance cut would be a meaningful negative, while further clinical progress could support the longer-term diversification effort. Sector momentum may help, but weaker jobs data could increase pressure on healthcare names.